Successful treatment of refractory lupus erythematosus profundus with the interleukin-6 antagonist tocilizumab: a case report

Lupus. 2020 Jun;29(7):791-794. doi: 10.1177/0961203320913944. Epub 2020 Mar 19.

Abstract

Lupus erythematosus profundus (LEP) is an unusual form of cutaneous lupus erythematosus (CLE) characterized by multiple subcutaneous induration and associated with considerable physical and psychological morbidity. The heterogeneity of CLE makes it difficult to understand its underlying pathogenesis and represents a therapeutic challenge. Recently, new insight into the pathogenesis of CLE has implicated various cytokines, opening doors to targeted biologic agents. We report a case of a 23-year-old female who presented with refractory LEP ulcers as an initial presentation of systemic lupus erythematosus. The lesions were resistant to multiple conventional therapies and remarkably responded to tocilizumab.

Keywords: Lupus erythematosus profundus; cutaneous lupus erythematosus; refractory ulcers; systemic lupus erythematosus; tocilizumab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Female
  • Humans
  • Interleukin-6 / antagonists & inhibitors*
  • Panniculitis, Lupus Erythematosus / drug therapy*
  • Panniculitis, Lupus Erythematosus / pathology
  • Recurrence
  • Skin Ulcer / etiology*
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Interleukin-6
  • tocilizumab